罕见变异与特发性肺纤维化患者生存:多中心观察性队列研究及独立验证
研究基于PFFPR队列888例和PROFILE队列472例IPF患者,评估单基因成人起病肺纤维化基因的合格罕见变异与生存的关系。
要点
- 携带单基因肺纤维化基因合格罕见变异的IPF患者生存更短。
- PRS-IPF最低的IPF患者同样表现出更差的生存。
- 罕见变异与常见风险变异对生存存在非相加效应,提示不同疾病亚型。
核心结论
- 单基因成人起病肺纤维化基因的合格罕见变异与IPF患者更短生存相关。
- PRS-IPF最低的IPF患者生存也更差,且罕见变异与常见风险变异存在非相加效应。
研究设计与样本
- 多中心观察性队列研究,PFFPR队列纳入888例临床诊断IPF患者,采用全基因组测序识别合格变异。
- 独立验证队列PROFILE纳入472例IPF患者,两队列合计1360例参与者。
- 主要结局为合格变异与生存的关联,次要结局为合格变异与PRS-IPF的关联。
- 采用logistic回归(调整性别、诊断年龄和遗传异质性主成分)和Cox比例风险模型(调整基线混杂因素),并在固定效应模型下进行荟萃分析。
主要发现
- 上述结果在PROFILE队列中得到验证,荟萃分析显示两队列效应方向一致。
临床怎么用
- 评估IPF患者携带单基因成人起病肺纤维化基因合格变异的状态,可能有助于预测疾病进展。
- 结合PRS-IPF建模,可能为IPF患者疾病进展预测提供额外信息。
- PRS可能用于指导测序优先级的选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rare pathogenic variants in telomere-related genes are associated with poorer clinical outcomes in idiopathic pulmonary fibrosis (IPF). We aimed to assess whether rare qualifying variants in monogenic adult-onset pulmonary fibrosis genes are associated with IPF survival. Using polygenic risk scores (PRS), we also evaluated the influence of common IPF risk variants in patients carrying the qualifying variants. METHODS: We identified qualifying variants in telomere and non-telomere genes using whole-genome sequences from individuals clinically diagnosed with IPF and enrolled in the Pulmonary Fibrosis Foundation Patient Registry (PFFPR), a large multicentre, observational cohort study (March 29, 2016 to June 15, 2018, n=888). We also derived a PRS for IPF (PRS-IPF) from known common sentinel IPF variants. The primary outcome was the association between qualifying variants and survival. The secondary outcome was the association between qualifying variants and PRS-IPF. We used logistic regression models adjusted for sex, age at diagnosis, and principal components of genetic heterogeneity to examine the mutual relationship of qualifying variants and PRS-IPF. The association between qualifying variants and PRS-IPF with survival was tested using Cox proportional hazard models adjusted for baseline confounders. Validation of the results was sought in data from an independent multicentre, prospective, observational cohort study of IPF in the UK (PROFILE, May 17, 2010 to Sept 5, 2017, n=472), and results were meta-analysed under a fixed-effects model. FINDINGS: We included 888 patients from PFFPR and 472 from PROFILE, totalling 1360 participants. In the PFFPR, carriers of qualifying variants in monogenic adult-onset pulmonary fibrosis genes were associated with lower PRS-IPF (odds ratio 1·79 [95% CI 1·15-2·81]; p=0·010) and shorter survival (hazard ratio 1·53 [1·12-2·10]; p=7·33 × 10-3). Individuals with the lowest PRS-IPF also had worse survival (1·61 [1·25-2·07]; p=1·87 × 10-4). These findings were validated in PROFILE and the meta-analysis of the results showed a consistent direction of effect across both cohorts. INTERPRETATION: We found non-additive effects between qualifying variants and common risk variants in IPF survival, suggesting distinct disease subtypes and raising the possibility of using PRS to guide sequencing prioritisation. Assessing the carrier status for qualifying variants and modelling PRS-IPF promises to further contribute to predicting disease progression among patients with IPF. FUNDING: Instituto de Salud Carlos III; Instituto Tecnológico y de Eenergías Renovables; Cabildo Insular de Tenerife; Fundación DISA; National Heart, Lung, and Blood Institute of the US National Institutes of Health; and UK Medical Research Council.
引用
- Alonso-González A, Jáspez D, Lorenzo-Salazar JM, et al. Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation. Lancet Respir Med. 2025. PMID: 40311650. doi:10.1016/S2213-2600(25)00045-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。